A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 39, Issue 2, 2003, Pages 191-196

  Winegarden, Jerome D ^a   Mauer, Ann M ^a   Gajewski, Thomas F ^a   Hoffman, Philip C ^a   Krauss, Stuart ^a   Rudin, Charles M ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Bryostatin 1; Myalgia; Non small cell lung cancer; Paclitaxel

Indexed keywords

BRYOSTATIN 1; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; INTERLEUKIN 6; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOMETRY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PAIN; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT DISEASE; T LYMPHOCYTE; THROMBOCYTOPENIA; TOXICITY; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; LACTONES; LUNG NEOPLASMS; MACROLIDES; MALE; MIDDLE AGED; PACLITAXEL; PREMEDICATION; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037312095     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00447-6     Document Type: Article

References (16)

1. Vokes EE, Raben A. Non-small cell lung cancer. 5th ed. In: Devita VT, Rosenberg SA, editor, Cancer priniciples and practice of oncology, Lippincott-Raven. 2000, pp. 858-877.
2. Hoffman P.C., Mauer A.M., Vokes E.E. Lung cancer. Lancet. 355:(9202):2000;479-485.
3. Chemotherapy for advanced non-small cell lung cancer. In: Pass HI, Johnson DH, Turrisi AT, Minna JD, editors. Lung cancer principles and practice, 2nd ed. Lippincott Williams & Wilkins, 2000:889-903.
4. Schiller J.H., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:(2):2002;92-98.
5. Newton A. Regulation of protein Kinase C. Curr. Opin. Cell. Biol. 9:1997;161-167.
6. Isakov N., et al. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. J. Immunol. 150:(4):1993;1195-1204.
7. Esa A.H., et al. Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors. Int. J. Immunopharmacol. 12:(5):1990;481-490.
8. Tilden A.B., Kraft A.S. The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity. J. Immunother. 10:(2):1991;96-104.
9. Philip P.A., et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst. 85:(22):1993;1812-1818.
10. Koutcher J.A., et al. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin. Cancer Res. 6:(4):2000;1498-1507.
11. Wang S., et al. Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem. Pharmacol. 56:(5):1998;635-644.
12. Fidias P., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin. Cancer Res. 7:(12):2001;3942-3949.
13. Akerley W. III. Paclitaxel in advanced non-small cell lung cancer: an alternative high-dose weekly schedule. Chest. 117:(4 Suppl. 1):2000;152S-155S.
14. Hickman P.F., et al. Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br. J. Cancer. 72:(4):1995;998-1003.
15. Kemp G.J., et al. Regulation of oxidative and glycogenolytic ATP synthesis in exercising rat skeletal muscle studied by 31P magnetic resonance spectroscopy. NMR Biomed. 9:(6):1996;261-270.
16. Kaubisch A, Kelsen DP, Saltz L, Kemeny N, O'Reilly E, Ilson D, Endres S, Barazzuol J, Schwartz GK. A phase I trial of weekly sequential bryostatin-1 (BRYO) and paclitaxel in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999 (Abstract).